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Background: Responsiveness, defined as the ability to detect a meaningful change, is a core psychometric
property of an instrument measuring quality of life (QoL) rarely reported in multiple sclerosis (MS) studies.
Objective: To assess the responsiveness of the Multiple Sclerosis International Quality of Life (MusiQoL)
questionnaire to change in disability over 24 months, defined by change in the Expanded Disability Status Scale
(EDSS) score.
Methods: Patients with MS were enrolled into a multicenter, longitudinal observational study. QoL was assessed
using both the MusiQoL and the 36-Item Short-Form (SF-36) instruments at baseline and every 6 months thereafter
up to month 24; neurological assessments, including EDSS score, were performed at each evaluation.
Results: The 24-month EDSS was available for 524 patients. In the 107 worsened patients, two specific dimensions
of MusiQoL, the sentimental and sexual life and the relationships with health care system dimensions, and ‘physical’
scores of SF-36 showed responsiveness.
Conclusions: Whereas specific dimensions of MusiQoL identified EDSS changes, the MusiQoL index did not detect
disability changes in worsened MS patients in a 24-month observational study. Future responsiveness validation
studies should include longer follow-up and more representative samples.
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Multiple sclerosis (MS) is a chronic inflammatory de-
myelinating disease of the central nervous system that
affects from 1 to 8 per 100.000 young adults [1]. While
the physical disability is of great importance in (MS), it
is now well-recognized that it does not reflect all the
aspects that patients consider important in their life.
It is only one aspect of a person’s experience, and MS is
associated with a significant decreased health-related
quality of life (QoL) [2,3]. So, monitoring QoL is import-
ant as patients report that many aspects of the disease
affect their QoL. Although QoL instruments potentially* Correspondence: karine.baumstarck@univ-amu.fr
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disability assessment based on the Expanded Disability
Status Scale (EDSS) [2,4-6], it is a complex task to valid-
ate their relationship to the disease in question. One
potential method of validation is to assess the associ-
ation between disability change and change in the QoL
instrument, termed ‘responsiveness’ or ‘sensitivity to
change’. This property, defined as the ability to detect a
meaningful change, is a core psychometric property of a
measuring instrument [7-9]. However, examination of
responsiveness requires longitudinal data collection and
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is a well-validated MS-specific, self-administered, multi-
dimensional, patient-based QoL instrument [10] initially
co-developed and validated in 14 languages. In the initial
MusiQoL validation study, responsiveness was assessed
in a small sample size at day 21 [10].
The present study sought: i) to assess the responsive-
ness of MusiQoL to changes in disability over 24 months
in patients with MS, defined by changes in the EDSS
score [11,12]; ii) to compare the responsiveness between
MusiQoL and a generic instrument (SF-36).
Methods
Study design and setting
This was a multicenter, multiregional, longitudinal study
carried out at 32 centers in 12 countries (see Additional
file 1: Table S1): Argentina (3 centers), Australia (5),
Austria (3), Germany (3), Spain (1), France (2), Israel (5),
Italy (5), Norway (1), Turkey (1), the United Kingdom (2),
and the United States (1). This was a study investigator-
initiated.
Standard protocol approvals, registrations, and patient
consent
This study (ClinicalTrials.gov identifier: NCT00702065)
was performed in accordance with the Declaration of
Helsinki and all applicable regulatory authority require-
ments and national laws. Written informed consent from
patients was obtained prior to any study procedures.
Patients
Patients were eligible for the study if they were aged
18 years or older, had any form of definite MS (2001 or
2005 McDonald [13] and/or Poser criteria [14]), had an
EDSS score ≤7.0, were with or without treatment includ-
ing disease-modifying drugs, and were able to complete
the QoL questionnaires independently. Patients were eli-
gible regardless of approved MS treatment received. Pa-
tients were excluded if they were in clinically isolated
syndrome status, were receiving or assigned to receive
any investigational drug or undergo any experimental
procedure during the study, or had a major medical or
psychiatric illness (including dementia). All therapeutic
decisions during the study were at the discretion of the
treating physician.
Assessments and data collection
Clinical data and MS treatments were recorded by the
physician using an electronic case report form. QoL data
were collected using paper questionnaires, which were
completed by patients in the waiting room of the cen-
ters. Five assessments were performed in total: at the
time of enrollment (baseline evaluation), and every
6 months thereafter up to month 24.Demographic and clinical data
Demographic data and history of MS, including MS
course, number of relapses within the previous 24 months,
date of disease onset, and all ongoing MS treatments, were
collected at baseline. At baseline and subsequent evalua-
tions, patients underwent a neurological evaluation, in-
cluding and MS course. Neurological disability status was
assessed using a neurologist-rated Expanded Disability
Status Scale (EDSS) including eight Functional Systems
scores (FS) [15]: pyramidal, cerebellar, brainstem, sensory,
bowel and bladder, visual, cerebral, and other. Each of the
FSS is an ordinal clinical rating scale ranging from 0 to 5
or 6. The EDSS is an ordinal clinical rating scale ranging
from 0 (normal neurologic examination) to 10 (death due
to MS). Treatment and clinical relapses (defined as the ap-
pearance of a new symptom or group of symptoms, or the
worsening/reappearance of old symptoms lasting at least
24 hours, in the absence of fever and preceded by stability
or improvement for at least 30 days) were also recorded.
Quality of life
QoL was assessed at baseline and at all subsequent as-
sessments using two questionnaires, the MusiQoL and
the Short Form 36 (SF-36).
The MusiQoL questionnaire comprises 31 questions
in 9 dimensions (subscales): activities of daily living
(ADL, 8 items), psychological well-being (PWB, 4),
symptoms (SPT, 4), relationships with friends (RFr, 3),
relationships with family (RFa, 3), sentimental and sexual
life (SSL, 2), coping (COP, 2), rejection (REJ, 2), and rela-
tionships with healthcare system (RHCS, 3). The index
score is computed as the mean of these subscale scores.
All 9 dimensions and the index score are linearly
transformed and standardized on a 0 to 100 scale, where
0 indicates the worst possible level of QoL and 100 indi-
cates the best level. Differential item functioning analysis
were performed in the initial validation study showing
satisfactory results across countries [10]. The SF-36
(version 2) questionnaire comprises 36 items grouped
into 8 subscales; two standardized summary scores are
also derived: physical component summary (PCS) and
mental component summary (MCS). The PCS and
MCS scores are norm-based, using a linear T-score
transformation with a mean of 50 and a standard devi-
ation of 10. Scores range from 0 to 100, with higher
values indicating better QoL.
Worsened and non-worsened patients
Patients were defined as worsened or non-worsened
based on change in EDSS score from baseline to month
24. The worsened patient group was characterised by a
24-month increase in the EDSS score by one point if the
baseline EDSS score was less than 5.5, or an increase in
the EDSS score by half a point if the baseline EDSS score
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as non-worsened [16,17].
Study outcomes
The population analysed included all patients with a
MusiQoL assessment at baseline and at a subsequent as-
sessment, and EDSS score at baseline and at the same
subsequent assessment. The primary outcome was the
change in MusiQoL scores between baseline and month
24 [18]. Secondary outcomes were: change in MusiQoL
scores between baseline and each of months 6, 12, and
18; changes in MusiQoL subscale scores and SF-36
subscale and summary scores between baseline and each
subsequent visit.
Statistical analysis
Comparisons between the two groups, worsened or non-
worsened patients, were performed using a chi-square
test for categorical variables or a Mann–Whitney test for
quantitative variables. The effect size (ES) was calculated
as the mean change in QoL (MusiQoL and SF-36) scores
between baseline (BL) and i-month (Mi: M6, M12, M18,
and M24) divided by the standard deviation of the base-
line score [8]. An ES of at least 0.2 is recommended as
the standard for supporting a minimal sensitivity to
change. ES of 0.2, 0.5 and 0.8 is considered as small,
moderate and large change respectively [18,19]. To
quantify how the responsiveness differs between the
worsened and non-worsened patients, standardized vari-
ations between i-month and BL were calculated as the
final QoL value minus the initial QoL value divided by
the initial QoL value for each patient and for each QoL
score. Standardized variations were compared between
worsened or non-worsened patients using Mann–Whit-
ney tests. A two-sided paired t-test at 5% significance
level was used to assess whether the change in the QoL
scores from baseline to month 24 was significantly dif-
ferent from zero. To assess change over time of QoL di-
mensions in each groups (worsened or non-worsened
groups), mixed linear modeling was performed using un-
structured covariance matrix after adjusted for covari-
ates: gender, age, marital status, employment status,
education level, and disease duration. The annualized re-




In total, 600 patients were enrolled from 12 countries
between November 2007 and October 2010; 1 patient
was excluded because of a protocol violation (eligibil-
ity requirements not met) and 19 patients were ex-
cluded due to missing QoL data at months 6, 12, 18,
and 24 (Figure 1). The final sample comprised 580patients. The 24-month EDSS was available for 524 of
536 patients assessed at 24-month. A total of 417
(79.6%) patients were defined as non-worsened and
107 (20.4%) patients were defined as worsened. The
baseline demographic characteristics differed between
worsened and non-worsened subjects, with worsened
patients on average being older, with higher baseline
EDSS scores and a higher proportion of primary and
secondary progressive MS than non-worsened patients
(Table 1). At inclusion, 551 (95.0%) patients were tak-
ing disease-modifying drugs. Over the course of the
study, 366 patients (63.1%) were relapse free. In total,
204 patients had ≥1 relapse (data were unavailable for 10
patients); of these patients, most had either one (n = 137)
or two (n = 42) relapses; 4 patients had ≥5 relapses. The
mean (SD) number of relapses occurring during the study
was 0.54 (0.90) and the annualized relapse rate was 0.28
(95% confidence interval: 0.25, 0.31). The mean (SD)
change from baseline in EDSS score was −0.03 (0.71) at
month 6, -0.03 (0.86) at month 12, -0.01 (0.91) at month
18, and 0.03 (0.95) at month 24.
Responsiveness of MusiQoL and SF-36 at month 24 in
worsened patients
In worsened patients, two MusiQoL dimensions, senti-
mental and sexual life and relationships with healthcare
system, had an ES higher than 0.20 at month 24 (Table 2),
indicating an association with disability change. The stan-
dardized variation of the activity of daily living dimension
and the sentimental and sexual life dimension of MusiQoL
were statistically different between worsened group and
non-worsened groups. The ES of the physical component
summary and two dimensions of the SF-36 (physical func-
tioning and bodily pain) were higher than 0.20. For the
SF-36 physical component summary score, and 3 dimen-
sions of SF-36 (physical functioning, role physical, and
bodily pain), the standardized variations were statistically
different between worsened and non-worsened patients
(Tables 2 and 3).
Responsiveness of MusiQoL and SF-36 at months 6, 12,
and 18 in worsened patients
A small ES was obtained for the relationships with
healthcare system dimension at all assessments, for rela-
tionships with family at month 12, and for sentimental
and sexual life at month 18 (Table 2). The physical com-
ponent summary and the bodily pain dimension of SF-
36 at month 18 showed some responsiveness in wors-
ened patients, lower than −0.20 (Table 2). At month-18,
the standardized variations were statistically different be-
tween worsened and non-worsened patients for the
index and 3 dimensions of MusiQoL (activity of daily
living, psychological well-being, and sentimental and
sexual life), and for the physical component summary
Figure 1 Patient disposition.
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physical) (Tables 2 and 3). In the earliest evaluation visits
(6 and 12 months), neither subscale scores nor composite
scores of SF-36 were associated with EDSS changes.
Changes in QoL scores over the time
In the worsened patients, dimensions showed significant
change over time after adjustment for covariates: activity
of daily living, relationships with healthcare system, and
sentimental and sexual life (respective p-values: 0.04,
<10-3, and 0.001) for MusiQoL, and physical functioning,
role physical, bodily pain, and the physical component
summary (all p-values: < 0.001) for SF-36. In the non-
worsened group, 4 dimensions of MusiQoL showed sig-
nificant changes (psychological well-being relationships
with family, relationships with healthcare system, and
coping; respective p-values:<10-3, 0.04, 0.02, and 0.03),
and 2 of SF-36 (role physical and general health, p = 0.03
and 0.02 respectively). These significant changes were in
accordance with the calculated ES, showing the higher
ES for these dimensions.
Discussion
This is the first study that reports details of the respon-
siveness of a MS-specific QoL questionnaire, theMusiQoL, in a large longitudinal study. Compared to
the international and European MS populations [10,20],
our patients presented a lower sex-ratio (0.38 versus
0.41 and 0.60, respectively), a less severe disability profile
(EDSS median 2.4 versus 3.2 and 4.1, respectively), and a
lower proportion of secondary progressive MS (9% ver-
sus 21% and 36%, respectively). These disparities may
partially explain the higher QoL scores reported by this
population compared to others.
QoL scores of both the MS-specific and generic in-
struments were weakly responsive to EDSS change be-
tween baseline and month 24. However, while the SF-36
detected changes only almost from the ‘physical-like’ di-
mensions (physical functioning, bodily pain, and psych-
ical component summary), the MusiQoL identified
EDSS changes from ‘non-physical’ dimensions, such as
relationships with healthcare system and sentimental
and sexual life. This weak responsiveness should not be
explained by the short nature of some scales (because
high ES were found for short dimensions), neither by
the conceptual basis of the questionnaire elaboration,
that was clearly defined in the initial publication [10].
Standardized variations of the MusiQoL differed signifi-
cantly between worsened and non-worsened patients for
‘psychological-like’ dimensions, such as psychological







N = 580 N = 107 N = 417 p
Female, n (%) 419 (72.2) 75 (70.1) 300 (71.9) 0.71
Age (years) M (SD) 41.3 (10.2) 43.2 (10.2) 40.9 (10.1) 0.02
Min, max 18, 71 19, 64 18, 69
Marital status, n (%) Cohabiting/married
Divorced/separated/single/widowed
393 (67.8) 73 (68.2) 282 (67.6) 0.91
187 (32.2) 34 (31.8) 73 (68.2)
Employment status, n (%) Employed 335 (57.8) 59 (55.1) 241 (57.8) 0.62
Unemployed/homemaker/retired/
student
245 (42.2) 48 (44.9) 176 (42.2)
Educational level, n (%) Elementary school 113 (19.5) 31 (28.4) 76 (18.2) 0.03
College 81 (14.0) 9 (8.3) 61 (14.6)
High school/university 386 (66.6) 67 (63.3) 280 (67.1)
EDSS score M (SD) 2.9 (1.9) 3.5 (2.2) 2.8 (1.8) <10-3
Median 2.5 4.0 2.0
Min, max 0.0, 7.5 0.0, 7.0 0.0, 7.0
MS course, n (%) Relapsing-remitting 510 (87.9) 79 (73.8) 381 (91.4) <10-3
Secondary progressive 53 (9.1) 18 (16.8) 30 (7.2)
Primary progressive 12 (2.1) 8 (7.5) 2 (0.5)
Primary relapsing 5 (0.9) 2 (1.9) 4 (1.0)
Time since first MS symptom (years) M (SD) 10.0 (7.5) 10.2 (8.1) 9.9 (7.2) 0.98
Min, max 0, 45 0, 45 0.0, 40
Number of relapses in previous
2 years
M (SD) 1.3 (1.4) 1.4 (1.6) 1.3 (1.3) 0.33
0 187 (32.2) 37 (34.6) 135 (32.4)
1 185 (31.9) 27 (25.2) 137 (32.9)
2 123 (21.2) 23 (21.5) 87 (20.9)
> = 3 85 (14.7) 20 (18.7) 58 (13.9)
M (SD), mean (standard deviation).
EDSS, Expanded Disability Status Scale; MS, multiple sclerosis.
° the 24-month EDSS was not available for 56 individuals.
* defined as worsened or non-worsened based on change in EDSS score from baseline to month 24 according to the definition of Lublin [Lublin 1996] and
Kappos [Kappos 2004].
Bold values: p-value < 0.05.
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36 seems to capture mostly QoL deficits due to physical
changes, MusiQoL, via specific dimensions such as senti-
mental and sexual life, detects emotional and social aspects
of the MS disease process often underestimated by clinical
judgment. Lastly, the MusiQoL index (at month-18)
detected a global change whereas only the physical com-
posite of the SF-36 and not the mental composite score
demonstrated responsiveness to EDSS change.
In our analysis, we did not find convincing differences
of responsiveness between MusiQoL and SF-36 sub-
scales. These findings were not in line with previous
reports indicating that specific instruments are poten-
tially more responsive and more sensitive for detecting
and quantifying small disease state changes than generic
health status measures [21,22], observations that have
also been specifically reported in MS [23,24]. Anyway,we consider the consensus that both general and specific
tools are needed in order to provide a comprehensive as-
sessment of global health and disease specific issues is
still valid [22]. Generic instruments are generally used to
compare QoL across different populations, while
disease-specific instruments focus on particular health
problems and are more sensitive for detecting and quan-
tifying small changes. In MS clinical practice, MS-
specific questionnaires are more appropriate due to a
better ability to discern QoL differences in patients than
the SF-36. Authors demonstrated that modifying existing
measures by adding items may not be useful in improv-
ing the measurement properties of an instrument [25].
The responsiveness of QoL instruments to EDSS
change reported in this study can be considered low
whatever the evaluation times and the nature of the
questionnaire, generic or MS-specific. Capacity to detect
Table 2 Responsiveness of MusiQoL and SF-36 in the 107 worsened patients
Baseline Month 6 Month 12 Month 18 Month 24
MusiQoL M (SD) M (SD) DM6-BL ES M (SD) DM12-BL ES M (SD) DM18-BL ES M (SD) DM24-BL ES
ADL 50.0 (24.4) 46.9 (25.2) −3.33 −0.14 49.4 (26.1) −1.04 −0.04 47.1 (26.9) −3.04 −0.12 46.8 (28.2) −3.53 −0.14
PWB 62.6 (22.1) 62.5 (23.0) −0.56 −0.02 64.8 (22.5) 2.04 0.09 61.7 (23.2) −1.33 −0.06 64.3 (23.9) 1.67 0.08
SPT 64.7 (21.3) 68.1 (21.6) 3.54* 0.16 69.2 (20.4) 4.29** 0.20 65.3 (21.6) 0.22 0.07 67.2 (21.3) 2.16 0.10
RFr 62.2 (25.0) 59.3 (24.6) −2.72 −0.11 60.3 (24.0) −1.33 −0.05 64.4 (23.4) 1.55 0.06 60.3 (23.6) −1.67 −0.07
RFa 74.6 (22.5) 73.2 (21.9) −1.35 −0.06 69.7 (25.3) −4.46 −0.20 73.4 (23.0) −1.83 −0.08 72.6 (23.2) −2.17 −0.10
SSL 63.3 (29.4) 59.5 (28.7) −3.65 −0.12 57.7 (29.3) −4.89* −0.16 54.3 (30.5) −9.62*** −0.32 56.1 (30.6) −6.38* −0.21
COP 66.1 (27.0) 66.7 (26.1) 0.36 0.01 67.2 (26.1) 0.12 0.00 67.3 (27.2) 1.14 0.04 64.5 (28.6) −0.73 −0.03
REJ 78.7 (27.7) 78.1 (24.4) −0.36 −0.01 79.4 (23.8) 0.61 0.02 78.1 (24.8) −0.38 −0.01 78.2 (24.8) −0.12 −0.00
RHCS 86.8 (14.8) 82.6 (19.1) −4.49** −0.30 82.9 (17.2) −3.96** −0.27 81.9 (20.4) −4.93** −0.33 80.7 (19.7) −5.98*** −0.40
Index 67.0 (13.1) 65.8 (13.9) −1.12 −0.09 66.1 (13.1) −1.08 −0.08 65.7 (13.8) −2.46** −0.19 65.2 (15.0) −2.26 −0.17
SF-36v2 M (SD) M (SD) DM6-BL ES M (SD) DM12-BL ES M (SD) DM18-BL ES M (SD) DM24-BL ES
PF 48.4 (28.5) 45.2 (29.0) −2.95 −0.10 46.6 (29.8) −2.19 −0.08 42.9 (30.4) −5.37** −0.19 41.1 (32.0) −7.84*** −0.28
RP 50.4 (27.9) 50.3 (28.8) −0.04 −0.00 50.9 (28.1) −0.55 −0.02 45.1 (27.8) −4.60 −0.17 46.0 (29.8) −4.83* −0.17
BP 67.6 (26.3) 64.1 (26.7) −3.88 −0.15 64.1 (25.7) −3.10 −0.12 61.6 (28.2) −5.88** −0.22 60.9 (27.3) −7.44*** −0.28
GH 49.5 (21.2) 50.2 (18.8) 0.89 0.04 47.4 (20.1) −2.83 −0.13 49.3 (20.0) −0.59 −0.03 47.9 (21.4) −2.27 −0.11
Vi 43.5 (18.3) 45.7 (20.2) 2.08 0.11 44.6 (19.6) 1.04 0.06 43.1 (19.4) −0.58 −0.03 44.1 (20.3) 0.58 0.03
SF 65.8 (24.1) 64.9 (25.5) −1.09 −0.04 65.3 (27.4) −0.25 −0.01 65.0 (25.5) −0.98 −0.04 61.9 (28.7) −3.85 −0.16
RE 53.0 (14.9) 54.8 (12.5) 1.29 −0.09 52.5 (13.3) −0.59 −0.04 52.8 (13.7) −0.80 −0.05 51.7 (14.4) −1.94 −0.13
MH 65.4 (18.7) 66.8 (18.0) 0.98 0.05 64.6 (20.5) −1.04 −0.06 64.3 (18.2) −1.85 −0.10 63.2 (20.4) −3.12 −0.17
PCS 39.6 (9.9) 38.1 (9.8) −1.19 −0.12 38.9 (9.5) −0.93 −0.09 37.4 (10.6) −2.13** −0.22 37.3 (11.1) −2.59*** −0.26
MCS 44.9 (8.6) 46.2 (8.5) 1.30 0.15 45.1 (8.6) 0.50 0.06 45.1 (8.1) 0.16 0.02 45.1 (8.9) −0.11 −0.01
MusiQoL Multiple Sclerosis Quality of Life questionnaire.
ADL activity of daily living, PWB psychological well-being, SPT symptoms, RFr relationships with friends, RFa relationships with family, SSL sentimental and sexual
life, COP coping, REJ rejection, RHCS relationships with health care system.
SF-36v2 Short Form 36 version 2.
PF physical functioning, RP role physical, BP bodily pain, GH general health, Vi vitality, SF social functioning, RE role-emotional, MH mental health, PCS physical
component summary, MCS mental component summary.
M (SD), mean (standard deviation).
DMi-BL: difference mean between the score of the evaluation time and the baseline score (a positive difference indicates a QoL improvement and a negative
difference indicates a QoL deterioration), *p < =0.05, **p < =0.01, ***p < =0.001.
ES, effect size; bold values indicate effect sizes > = 0.20.
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ation of our study, in that 24-month follow-up was per-
haps too short to detect associations, in particular as a
lower number of patients than expected “worsened” in
comparison to historical data [26], which reduced the
power of the study to detect responsiveness.
Additionally, the relapse rate was low throughout the
study, indicating a population with relatively low disease
activity. Future responsiveness validation studies should
include longer follow-up or, perhaps, focus on patients
who would be expected to have more rapidly worsening
disability, for example patients with progressive forms of
MS. We chose not to do this during the planning of the
study because we wished to investigate QoL responsive-
ness across a wide range of patients with differing disease
severities. Of course, one might not expect large effect
sizes in responsiveness studies of this kind, because QoL
instruments and physical disability rating scales do not
contain highly overlapping information, and the premiseof our validation study was the detection of any associ-
ation between QoL change and EDSS change, as evidence
for relevance of the QoL instruments in MS, rather than
expectation of strong associations. In general, the relation-
ships between QoL instrument change and physical dis-
ability progression is likely to be weak because, over time,
disability change is associated with new coping strategies
and adjustment, leading to response shifts [27,28]. This is
especially relevant for global QoL scores and affective-
emotional dimensions. Response shift is now known to
affect adaptation to a wide degree of health conditions, in-
cluding MS [29], the result of an adaptive response to a
changed health status, and as such is viewed as a positive
phenomenon.
Given the availability of many QoL instruments, little
research has surprisingly been conducted to test the
responsiveness of QoL tools in MS. Comparisons with
responsiveness indices for other QoL instruments in the
literature are difficult without a direct head-to-head
Table 3 Responsiveness of MusiQoL and SF-36 in the 417 non-worsened patients
Baseline Month 6 Month 12 Month 18 Month 24
MusiQoL M (SD) M (SD) DM6-BL ES pW/NW M (SD) DM12-BL ES pW/NW M (SD) DM18-BL ES pW/NW M (SD) DM24-BL ES pW/NW
ADL 62.8 (24.7) 64.7 (25.7) 1.97** 0.08 0.065 65.2 (24.6) 2.61*** 0.11 0.109 65.0 (26.1) 2.09*** 0.08 0.035 63.4 (26.4) 0.91 0.04 0.017
PWB 62.3 (23.8) 63.7 (24.7) 1.63 0.07 0.187 65.8 (23.7) 3.63*** 0.15 0.410 65.6 (25.2) 3.21*** 0.13 0.029 66.9 (25.0) 4.76*** 0.20 0.145
SPT 69.4 (22.3) 70.2 (22.3) 0.83 0.04 0.196 71.2 (21.0) 1.58 0.07 0.140 71.1 (23.0) 1.70 0.08 0.694 69.8 (23.2) 1.45 0.01 0.441
RFr 59.1 (29.0) 58.1 (27.8) −0.19 −0.01 0.601 58.6 (28.5) −0.19 −0.01 0.937 58.1 (28.1) −0.74 −0.03 0.301 58.8 (27.9) −0.20 −0.01 0.754
RFa 72.5 (27.7) 71.5 (28.2) −0.33 −0.01 0.136 69.9 (28.6) −2.26 −0.08 0.362 69.6 (28.8) −2.97* −0.11 0.792 70.0 (29.7) −2.29 −0.08 0.803
SSL 63.6 (29.7) 62.9 (29.9) −0.39 −0.01 0.383 62.4 (30.7) −1.12 −0.04 0.237 62.4 (30.3) −1.91 −0.06 0.010 63.2 (30.6) −0.03 −0.00 0.043
COP 62.1 (29.6) 64.8 (28.7) 3.12** 0.10 0.149 65.3 (29.1) 3.49** 0.12 0.370 65.6 (28.7) 3.65** 0.12 0.879 65.5 (28.2) 3.20* 0.11 0.467
REJ 82.6 (23.9) 84.2 (23.5) 1.88* 0.08 0.242 84.2 (22.8) 1.68 0.07 0.172 81.9 (24.4) −0.76 −0.03 0.749 82.3 (23.4) −0.22 −0.01 0.715
RHCS 85.2 (19.4) 84.7 (19.9) −0.60 −0.03 0.138 83.5 (20.6) −1.71 −0.09 0.517 83.5 (19.6) −2.13* −0.11 0.603 83.0 (18.8) −2.18* −0.11 0.219
Index 68.5 (14.8) 69.3 (15.0) 0.90 0.06 0.160 69.4 (15.4) 0.75 0.05 0.365 69.1 (16.4) 0.27 0.02 0.014 69.4 (15.6) 0.34 0.02 0.068
SF-36v2 M (SD) M (SD) DM6-BL ES pW/NW M (SD) DM12-BL ES pW/NW M (SD) DM18-BL ES pW/NW M (SD) DM24-BL ES pW/NW
PF 65.2 (27.7) 65.5 (27.4) 0.11 0.00 0.472 65.9 (28.0) 0.83 0.03 0.086 66.8 (29.0) 1.11 0.04 <10-3 65.4 (29.5) 0.30 0.01 <10-3
RP 60.2 (29.6) 62.0 (28.5) 1.63 0.06 0.733 63.1 (28.7) 3.08* 0.10 0.233 63.2 (28.8) 2.77* 0.09 0.016 63.1 (28.6) 3.06* 0.10 0.001
BP 66.8 (27.2) 66.9 (27.6) 0.08 0.00 0.628 67.5 (25.5) 0.36 0.01 0.866 68.2 (26.7) 1.12 0.04 0.139 67.0 (26.5) 0.28 0.01 0.044
GH 54.7 (22.4) 54.6 (22.4) −0.02 −0.01 0.766 54.9 (22.0) 0.10 0.00 0.107 53.1 (23.0) −1.35 −0.06 0.646 52.7 (23.7) −2.03* −0.09 0.859
Vi 48.8 (22.3) 49.3 (23.0) 0.72 0.03 0.667 50.0 (22.4) 1.22 0.05 0.779 50.4 (22.8) 1.54 0.07 0.681 48.7 (23.2) 0.09 0.00 0.965
SF 69.0 (26.6) 71.0 (27.0) 2.12 0.08 0.330 70.4 (27.2) 1.29 0.05 0.531 70.6 (26.2) 1.71 0.06 0.356 70.3 (26.3) 1.33 0.05 0.117
RE 56.1 (13.7) 56.0 (12.7) −0.08 −0.00 0.392 56.5 (12.0) 0.27 0.02 0.251 56.2 (11.5) −0.06 −0.00 0.466 56.2 (12.3) 0.04 0.00 0.124
MH 63.9 (20.5) 64.4 (21.3) 0.65 0.03 0.853 65.3 (19.5) 1.25 0.06 0.383 64.2 (20.6) 0.29 0.01 0.132 64.4 (20.7) 0.41 0.02 0.069
PCS 44.1 (10.0) 44.2 (10.1) 0.11 0.01 0.702 44.4 (10.1) 0.41 0.04 0.349 44.6 (10.5) 0.54 0.05 0.003 44.1 (10.5) 0.05 0.01 <10-3
MCS 43.8 (8.9) 44.2 (9.0) 0.38 0.04 0.260 44.3 (8.8) 0.48 0.05 0.773 44.0 (9.0) 0.04 0.00 0.973 44.0 (9.2) 0.20 0.02 0.700
MusiQoL Multiple Sclerosis Quality of Life questionnaire.
ADL activity of daily living, PWB psychological well-being, SPT symptoms, RFr relationships with friends, RFa relationships with family, SSL sentimental and sexual life, COP coping, REJ rejection, RHCS relationships with
health care system.
SF-36v2 Short Form 36 version 2.
PF physical functioning, RP role physical, BP bodily pain, GH general health, Vi vitality, SF social functioning, RE role-emotional, MH mental health, PCS physical component summary, MCS mental component summary;
M (SD), mean (standard deviation).
DMi-BL: difference mean between the score of the evaluation time and the baseline score (a positive difference indicates a QoL improvement and a negative difference indicates a QoL deterioration), *p < =0.05,
**p < =0.01, ***p < =0.001.
ES, effect size; bold values indicate effect sizes > = 0.20.
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tested are not comparable. Some features should be
discussed: i) the study design: two approaches have been
recommended for assessing responsiveness [30], from
observational studies where patients are treated with
usual medical care [23,24,31,32], and more often from
clinical studies of interventions where the intervention is
expected to produce a change in health [23,31-33]; ii)
the time between the 2 evaluations differ: 6 to 12 months
[32], 2 years [34], 5 years [24], or including a larger win-
dow (6–18 months) [31] in the longitudinal studies, and
from few weeks to months in the clinical studies, de-
pending on the expected time to show the intervention
effect [23,31,33,35,36]; iii) the methods to determine the
subject’s health status change: from ‘transition questions’
where the patient [36,37], or the physician, or both [31]
are asked to compare the current status to an earlier
time point, rarely from a EDSS deterioration, and some-
times absence of precise definition [23]; iv) the sample
size is often small [31] or not provided [23]. These dis-
parities complicate the choice of scales for studies,
which often involves extrapolating findings from studies
in different samples.
The representativeness of our sample should be
discussed. Compared with the most important longitu-
dinal studies that parallel the present study [38-40], our
patients were younger or older (mean ages of 42 [38], 44
[39], and 34 years [40], respectively), had less severe
baseline disability statuses (mean EDSS score of 4.1, 5.1,
and 2.9, respectively), had a sex-ratio of 3:1 (4:1, 2:1, and
2.5:1, respectively), and presented a low number of wors-
ened patients while Benito-Leon [41] identified 30% hav-
ing clinical progression of disability over an identical
follow-up period. The patients were consecutive outpa-
tients assessed in a context of MS treatment monitoring,
often presented a stable disease. These specificities may
partially be explained by a selection bias due to restrict-
ive inclusion criteria, which excluded the most severe in-
dividuals (baseline EDSS scores higher than 7.0) and
included a high proportion of patients treated with dis-
ease modifying therapies (95%).
Conclusion
This study showed that the MusiQoL may be incorpo-
rated in longitudinal studies to detect quality of life
changes in MS patients. The MusiQoL index score and
specific MusiQoL dimensions, such as relationships with
health care system or sentimental and sexual life, were
moderately responsive to disability change in MS pa-
tients over the course of this 24-month study. The
present study could also inform the longitudinal design
of future QoL responsiveness studies, in particular in re-
lation to the relatively small proportion of patients
exhibiting EDSS worsening over 24 months of follow-up.Future responsiveness validation studies should include
longer follow-up.
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